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Phosphatidylinositol-3-kinase (PI3K) and its members are classified into three classes, and class I PI3K regulates cell 
proliferation, growth, survival, and apoptosis.1 PI3K signal-
ing is initiated through multiple-receptor tyrosine kinases, 
including epidermal growth factor receptor (EGFR), human 
EGFR-2 (human epidermal growth factor receptor-2), insulin 
growth factor receptor (insulin growth factor-1R), vascular 
EGFR, platelet-derived growth factor, and Src family kinases.2 
Non–small-cell lung cancer (NSCLC) harbors numerous bio-
markers involved in the PI3K pathway, including PIK3CA 
amplification and mutation, decrease or loss of phosphate, and 
tensin homologue (PTEN), AKT mutation, KRAS mutation, 
LKB1 loss, and MET, EGFR, or HER2 mutation and ampli-
fication.3 PI3K has also been implicated in the expansion of 
bronchioalveoar stem cells.4 Because of the redundancy of 
activating receptors and negative feedback loops, targeting 
PI3K in the clinic has proved to be challenging, and a multi-
tude of strategies are being evaluated.
BKM120
BKM120 is an oral pan-class I PI3K inhibitor belong-
ing to the 2, 6-dimorpholino pyrimidine derivative family. It 
is a highly specific inhibitor of class I PI3K and has demon-
strated antiproliferative activity in tumor cell lines and xeno-
graft models, with or without PI3K/PTEN mutations.5 In the 
phase I trial the most common adverse events (AEs) were 
rash and gastrointestinal toxicities, in addition to hyperglyce-
mia and mood alterations.6 Inhibition of mammalian target of 
rapamycin (mTOR) results in an up-regulation of PI3K/AKT 
and combined mTOR inhibition with BKM120 resulted in 
a synergistic reduction in NSCLC tumor growth.7 An addi-
tional method for combined mTOR/PI3K inhibition may 
occur when PI3K inhibitors are combined with pemetrexed. 
Aminoimidazolecarboxamide ribonucleotide formyltransfer-
ase is a downstream target of pemetrexed, which promotes 
accumulation of cellular imidazole monophosphate, which 
activates adenosine monophosphate-activated protein kinase, 
and subsequently, blocks mTOR.8 A phase I trial will be initi-
ated to evaluate the recommended phase II dose of combi-
nation carboplatin, pemetrexed, and BKM120 in advanced 
NSCLC patients. Tumor biomarkers related to the PI3K sig-
naling pathway will be analyzed. Additional ongoing trials 
using BKM120 with chemotherapy relevant to lung cancer 
include combinations with carboplatin/paclitaxel, irinotecan, 
and paclitaxel alone.
GDC 0941
GDC 0941 is a competitive PI3K inhibitor, which 
induces cell-cycle arrest and apoptosis.9 A phase I trial of car-
boplatin, paclitaxel with or without bevacizumab, and GDC 
0941 as either first- or second-line therapy enrolled 41 patients. 
Neutropenia and febrile neutropenia were the most frequent 
grade 3/4 AEs seen. In patients with squamous cell carcinoma 
(SCC), a 71% overall response rate was demonstrated, whereas 
38% overall response rate was observed in the non-SCC. A ran-
domized phase II trial has been initiated to evaluate carboplatin, 
paclitaxel with GDC 0941 versus placebo followed by mainte-
nance GDC 0941 or placebo in SCC, and the combination with 
the addition of bevacizumab will be investigated in non-SCC 
and bevacizumab-eligible patients. This trial requires manda-
tory tissue collection for molecular evaluation of PI3K targets.
BAY 80–6946
BAY 80–6946 is a reversible, pan-class I, PI3k specific 
inhibitor, which is under investigation in multiple phase I clin-
ical trials. In a phase I dose-escalation study, the maximum 
tolerated dose (MTD) was 0.8 mg/kg and pharmacokinetics 
supported weekly dosing. The most common AEs included 
hyperglycemia requiring insulin after dosing, grade 1/2 
fatigue, nausea, vomiting, alopecia, diarrhea, mucositis, dys-
geusia, and grade 2/3 anemia. Tumor response was assessed 
by fluorodeoxyglucose-positron emission tomography, which 
demonstrated reduced uptake in a pancreatic cancer liver 
lesion and an NSCLC lesion.
PX866
PX866 is an irreversible, selective, oral PI3K inhibitor, 
which facilitates sustained blockade of PI3K signaling and 
does not exhibit significant off-target effects. It has demon-
strated activity in multiple tumor models as a single agent, and 
in combination with targeted agents, chemotherapy, and radia-
tion, including an NSCLC xenograft-model resistance to erlo-
tinib.10 A phase I trial of PX866 monotherapy investigating 
intermittent and continuous dosing schedules determined an 
MTD of 12 mg/day on the intermittent schedule and 8 mg/day 
on the continuous schedule. The continuous schedule demon-
strated similar safety with improved disease control over the 
intermittent dosing regimen. The most common AEs included 
diarrhea, nausea, vomiting, and liver function test abnormali-
ties. A subset of patients with PIK3CA mutation maintained 
disease control longer than those with PIK3CA wild-type or 
KRAS mutation. A phase I trial evaluating the combination of 
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docetaxel and PX866 in 43 patients showed improved tumor 
control in patients with PIK3CA mutations compared with 
those with wild-type or KRAS mutated tumors. A randomized 
phase II trial of the combination is being investigated in head 
and neck SCC and NSCLC, and a retrospective analysis of 
molecular characteristics will be performed.
ON 01910.NA
ON 01910.Na(rigosertib) is a potent and selective mitotic 
inhibitor, which arrests cell-cycle progression in G2/M phase 
by causing spindle abnormalities. It is a non-ATP–binding 
small-molecule inhibitor of polo-like kinase 1 (Plk1) result-
ing in mitotic arrest and apoptosis and has also been found to 
inhibit PI3K.11 The drug has demonstrated preclinical activity 
in multiple tumor types as monotherapy and combination ther-
apy. It inhibits PI3K at the mRNA level, resulting in decreased 
concentration of Cyclin D, c-myc, and other regulatory pro-
teins. In a phase I trial of ON-01910.Na in combination with 
gemcitabine, the combination did not add significant toxicity to 
that seen with gemcitabine alone. One patient with Hodgkin’s 
lymphoma experienced a partial response, and a patient with 
NSCLC experienced stable disease for 24 weeks.
AKT INHIBITION—MK 2206
Constitutive AKT activation is a driver of the malignant 
progress and associated with resistance to chemotherapy and 
radiotherapy. MK-2206 is an oral, allosteric pan-AKT inhibi-
tor, which has demonstrated preclinical activity in cell lines 
with PIK3CA mutation and amplification and PTEN loss. 
MK-2206 has been shown to overcome erlotinib resistance 
in both EGFR mutant and wild-type cell lines, demonstrating 
significant growth inhibition. A phase I trial determined an 
MTD of 60 mg on alternate days with AEs of rash, nausea, 
hyperglycemia, pruritis, and diarrhea.12 An ongoing phase II 
trial is evaluating erlotinib and MK-2206 in patients with prior 
response and subsequent progression to EGFR tyrosine kinase 
inhibitor therapy with EGFR mutant and wild-type cohorts. 
Dual inhibition with MK-2206 and AZK6244 (an MEK inhib-
itor) has shown potent antitumor effect in vitro and in vivo and 
is in development with a focus on KRAS activated tumors.13
FUTURE DIRECTIONS
PI3K serves as the site of convergence for multiple 
pathways resulting in complex regulation of signaling and the 
potential for significant off-target effects, including activation 
of alternative networks to promote oncogenesis. Tumors with 
PIK3CA mutations and PTEN loss have been most sensitive 
to PI3K inhibition, and mutated Ras has been identified as a 
potential mediator of PI3K resistance.14 Future trials will be 
focused on dual inhibition of targets to overcome negative 
feedback loops and mechanisms of resistance. The optimal 
development of PI3K inhibitors in lung cancer will require 
a better understanding of predictive biomarkers to determine 
patient populations that will derive the greatest benefit.
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